Dr. Rob Wüst published a Solve-funded study in "Trends in Endocrinology & Metabolism" examining how Long Covid and ME/CFS affect muscles and physical functioning.| Solve ME/CFS Initiative
The Solve ME/CFS Initiative (Solve M.E.) is proud to award research funds to Dr. Geraldine Cambridge and Dr. Dana Yelin, two world-class scientists who are finding new ways to treat people with Long Covid and ME/CFS.| Solve ME/CFS Initiative
Solve has selected Simmaron Research as the recipient of our latest ME/CFS Catalyst Award. The funds will be used to accelerate a low-dose rapamycin trial for ME/CFS, Long COVID, and other infection-associated chronic conditions (IACCs). The study advances an FDA-approved drug for reducing key symptoms of ME/CFS and Long Covid, repurposing rapamycin to reduce fatigue, orthostatic intolerance, post-exertional malaise, and sleep issues for a subset of people with ME/CFS.| Solve ME/CFS Initiative
2022 Solve Ramsay Research Grant winner Catherine Seton recently co-authored a review of cognitive dysfunction in ME/CFS.| Solve ME/CFS Initiative
In September, the NIH held a three-day workshop at its campus in Bethesda, Maryland, to discuss the path forward for RECOVER-TLC. In this blog, we’re summarizing Day 1 of the workshop in its entirety.| Solve ME/CFS Initiative